Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by inhibiting Wnt/β-catenin signaling

Li, Hui; Jiao, Shun Chang; Li, Xin; Banu, Hasina; Hamal, Shreejana; Wang, Xianrong

doi:10.1016/j.bbrc.2015.09.140

Cited by 53 publications

(50 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data support the essential roles of Wnt/β-catenin in ovarian cancer and are in line with previous work showing that targeting Wnt/β-catenin is an alternative therapeutic strategy in ovarian cancer treatment. Interestingly, recent studies revealed that 2 other anthelminthic/antibiotic drugs, niclosamide and tigecycline, also target Wnt/β-catenin in cancer cells [26,27]. …”

Section: Discussionmentioning

confidence: 99%

Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy

Zhang

et al. 2017

Med Sci Monit

View full text Add to dashboard Cite

BackgroundAberrant activation of Wnt/β-catenin has been shown to promote ovarian cancer proliferation and chemoresistance. Pyrvinium, an FDA-approved anthelmintic drug, has been identified as a potent Wnt inhibitor. Pyrvinium may sensitize ovarian cancer cells to chemotherapy.Material/MethodsThe effect of pyrvinium alone and its combination with paclitaxel in ovarian cancer was investigated using an in vitro culture system and in vivo xenograft models. The mechanisms of its action were also analyzed, focusing on the Wnt/β-catenin pathway.ResultsPyrvinium inhibited growth and induced apoptosis of paclitaxel- and cisplatin-resistant epithelial ovarian cancer cell lines A2278/PTX and SK-OV-3. Its combination with paclitaxel was synergistic in targeting ovarian cancer cells in vitro. In 3 independent ovarian xenograft mouse models, pyrvinium alone inhibited tumor growth. More importantly, we observed significant inhibition of tumor growth throughout the treatment when using pyrvinium and paclitaxel combined. Mechanistically, pyrvinium increased the Wnt-negative regulator axin and decreased the β-catenin levels in ovarian cancer cells. In addition, pyrvinium suppressed Wnt/β-catenin-mediated transcription, as shown by the decreased mRNA levels of MYC, cyclin D, and BCL-9. In contrast, the inhibitory effects of pyrvinium were reversed by β-catenin stabilization or overexpression, demonstrating that pyrvinium acted on ovarian cancer cells via targeting the Wnt/β-catenin signaling pathway.ConclusionsWe demonstrated that the anthelmintic drug pyrvinium targets ovarian cancer cells through suppressing Wnt/β-catenin signaling. Our work highlights the therapeutic value of inhibiting Wnt/β-catenin in ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy

Zhang

et al. 2017

Med Sci Monit

View full text Add to dashboard Cite

show abstract

“…Therefore, identification of the components of the Wnt/β-catenin pathway can provide promising targets for developing therapeutic agents. In a recent report, using the TOPflash reporter activity assay, Li et al (2015) found that TIG decreased the Wnt/β-catenin-mediated transcription in cervical squamous cell carcinoma and that overexpression of exogenous β-catenin could abolish the inhibitory effects of TIG on cancer cells.…”

Section: Wnt/β-catenin Signaling As a Target Of Tigmentioning

confidence: 99%

The Antibiotic Drug Tigecycline: A Focus on its Promising Anticancer Properties

Yan

et al. 2016

Front. Pharmacol.

View full text Add to dashboard Cite

Tigecycline (TIG), the first member of glycylcycline bacteriostatic agents, has been approved to treat complicated infections in the clinic because of its expanded-spectrum antibiotic potential. Recently, an increasing number of studies have emphasized the anti-tumor effects of TIG. The inhibitory effects of TIG on cancer depend on several activating signaling pathways and abnormal mitochondrial function in cancer cells. The aim of this review is to summarize the cumulative anti-tumor evidence supporting TIG activity against different cancer types, including acute myeloid leukemia (AML), glioma, non-small cell lung cancer (NSCLC), among others. In addition, the efficacy and side effects of TIG in cancer patients are summarized in detail. Future clinical trials are also to be discussed that will evaluate the security and validate the underlying the tumor-killing properties of TIG.

show abstract

“…Previously, we also found that tigecycline inhibited cell metastasis in melanoma via blocking the EMT . Tigecycline was shown to induce intrinsic caspase‐dependent apoptosis in ALL, retinoblastoma, cervical squamous cell carcinoma and NSCLC . However, tigecycline did not cause significant apoptosis in PDAC cells when tigecycline was used alone.…”

Section: Discussionmentioning

confidence: 82%

“…Then, we found that tigecycline also plays important roles in various solid tumours, such as gastric cancer, oral squamous cell carcinoma (OSCC), malignant melanoma, neuroblastoma and glioma . Meanwhile, other groups also found that tigecycline acts as a promising anti‐cancer drug for many other kinds of cancers, including triple‐negative breast cancer (TNBC), diffuse large B‐cell lymphomas (DLBCLs), cervical squamous cell carcinoma, ovarian cancer, hepatocellular carcinoma, chronic myeloid leukaemia (CML), prostate cancer and lung cancer . Recently, c‐Abl–specific tyrosine kinase inhibitors (TKIs) in combination with tigecycline were shown to be a promising strategy to treat patients with CML .…”

Section: Introductionmentioning

confidence: 99%

Antibiotic tigecycline inhibits cell proliferation, migration and invasion via down‐regulating CCNE2 in pancreatic ductal adenocarcinoma

Yang

Dong

Ren

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

Recently, many researches have reported that antibiotic tigecycline has significant effect on cancer treatment. However, biomedical functions and molecular mechanisms of tigecycline in human pancreatic ductal adenocarcinoma (PDAC) remain unclear. In the current study, we tried to assess the effect of tigecycline in PDAC cells. AsPC-1 and HPAC cells were treated with indicated concentrations of tigecycline for indicated time, and then, MTT, BrdU and soft agar assay were used to test cell proliferation. The effect of tigecycline on cell cycle and cellular apoptosis was tested by cytometry. Migration and invasion were detected by wound healing assay and transwell migration/invasion assay. Expressions of cell cycle-related and migration/invasion-related protein were determined by using Western blot. The results revealed that tigecycline observably suppressed cell proliferation by inducing cell cycle arrest at G0/G1 phase and blocked cell migration/invasion via holding back the epithelial-mesenchymal transition (EMT) process in PDAC. In addition, tigecycline also remarkably blocked tumorigenecity in vivo. Furthermore, the effects of tigecycline alone or combined with gemcitabine in vitro or on PDAC xenografts were also performed. The results showed that tigecycline enhanced the chemosensitivity of PDAC cells to gemcitabine. Interestingly, we found CCNE2 expression was declined distinctly after tigecycline treatment. Then, CCNE2 was overexpressed to rescue tigecycline-induced effect. The results showed that CCNE2 overexpression

show abstract

Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by inhibiting Wnt/β-catenin signaling

Cited by 53 publications

References 22 publications

Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy

Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy

The Antibiotic Drug Tigecycline: A Focus on its Promising Anticancer Properties

Antibiotic tigecycline inhibits cell proliferation, migration and invasion via down‐regulating CCNE2 in pancreatic ductal adenocarcinoma

Contact Info

Product

Resources

About